NCT04692766 - Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

January 24, 2022

Study Completion Date

March 22, 2022

Conditions

Pericarditis

Interventions

BIOLOGICAL

RPH-104

solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

DRUG

Placebo

Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package

Trial Locations (2)

"Federal State Budget Institution V.A. Almazov National Medical Research Center of Ministry of Healthcare of Russian Federation", Saint Petersburg

Federal Budgetary Healthcare Institution Orenburg Regional Clinical Hospital, Orenburg